Literature DB >> 8684796

Visual field loss after macular hole surgery.

S D Pendergast1, B W McCuen.   

Abstract

BACKGROUND: Vitrectomy has been successfully used for treating idiopathic macular holes. Although macular hole surgery has been successful and is generally regarded as a safe procedure, various complications have been reported. The authors report eight patients with symptomatic peripheral visual field loss occurring after vitrectomy for macular holes.
METHODS: Over a 3-year period, vitrectomy with removal of the posterior cortical vitreous and fluid-gas exchange was performed on 50 eyes of 47 patients with idiopathic macular holes. Eight patients reported visual field loss postoperatively, and Goldmann visual fields were obtained. The clinical characteristics and outcomes of the group of patients with visual field loss were compared with the group of patients without visual field loss.
RESULTS: Postoperatively, significant peripheral visual field loss was documented in eight patients. The macular holes were anatomically closed in seven eyes (87.5%) of these patients compared with 37 (88.1%) of 42 eyes in the group of patients with no symptomatic visual field loss. The visual field loss was not associated with age, sex, macular hole stage, postoperative intraocular pressure, or history of hypertension or coronary artery disease. The etiology of visual field loss was unclear in six patients.
CONCLUSION: Vitrectomy for idiopathic macular holes can result in significant peripheral visual field loss. The etiology of this complication usually is unknown.

Entities:  

Mesh:

Year:  1996        PMID: 8684796     DOI: 10.1016/s0161-6420(96)30565-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  18 in total

1.  Results of vitrectomy and the no-touch-technique using autologous adjuvants in macular hole treatment.

Authors:  H Hoerauf; H Klüter; E Joachimmeyer; J Roider; C Framme; P Schlenke; H Kirchner; H Lagua
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  The evaluation of a humidifying device for vitreoretinal surgery.

Authors:  B J T Vote; M K Russell; A Newland; P J Polkinghorne
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

Review 3.  [Macular hole. Survey and relevant surgical concepts].

Authors:  S Dithmar
Journal:  Ophthalmologe       Date:  2005-02       Impact factor: 1.059

4.  Peripheral visual field loss after vitreous surgery for macular holes.

Authors:  S Bopp; K Lucke; U Hille
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-06       Impact factor: 3.117

5.  Transient increase of retinal nerve fiber layer thickness after macular hole surgery.

Authors:  Nobuaki Hibi; Mineo Kondo; Kohei Ishikawa; Shinji Ueno; Keiichi Komeima; Hiroko Terasaki
Journal:  Int Ophthalmol       Date:  2014-06       Impact factor: 2.031

6.  Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.

Authors:  A Sciscio; A G Casswell
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

7.  Novel quantitative assessment of metamorphopsia in maculopathy.

Authors:  Emily Wiecek; Kameran Lashkari; Steven C Dakin; Peter Bex
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-18       Impact factor: 4.799

8.  Nonarteritic anterior ischemic optic neuropathy and 'visual field defects' following vitrectomy: could they be related?

Authors:  Mehran Taban; Hilel Lewis; Michael S Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-10-06       Impact factor: 3.117

9.  Intraocular humidity immediately after fluid-air exchange in pars plana vitrectomy.

Authors:  Nicole Eter; Ralf Brinken; Stephan Garbe; Manfred Spitznas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-13       Impact factor: 3.117

10.  Incomplete fluid-air exchange technique for idiopathic macular hole surgery.

Authors:  Bo-Jie Hu; Xue-Li Du; Wen-Bo Li; Yu-Wen Chang; Xing-Dong Shi; Teng Ma; Yong Wang; Yan-Hua He; Rui Niu; Wei-Na Cui
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.